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Supplementary Material 
 
Figure S1 
 
Figure S1. Cre-mediated mosaic recombination in the T-CreERT2 mouse line. (A) Schematic 
representation of the pTcreERT2 transgene used for the generation of the T-CreERT2 mouse 
line. (B) Cre-mediated recombination of the Rosa26-lacZ reporter inducing β-gal activity. (C) 
Whole-mount images of E12.5 T-CreERT2;Rosa26-lacZ embryos, stained for β-gal after 4-
OHT administration at E7.5, E8.5 or E10.5. (D) Same as in (C) but after 4-OHT 
administration at E7.5 with different doses of 4-OHT (5 to 500 µg). 
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Figure S2 
 
Figure S2. Body weight over time (A) and organ size at 6-month-old (B) of WT and 
MosMes-Pik3caH1047R mice. Data represent mean  SEM, n=30/genotype for (A), 
n=6/genotype for (B). 
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Figure S3 
 
Figure S3. Whole-mount endomucin-stained E9.5 embryos dosed with 170 g 4-OHT at 
E7.5. The MosMes-Pik3caH1047R embryo shows an overall less developed vasculature 
compared to the WT embryo. H, head; ov, otic vesicle; YS, yolk sac.  
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Figure S4 
 
Figure S4. MosMes-Pik3caH1047R mouse with a subcutaneous vascular malformation and 
dilated vein. (A,C) Ultrasound images with colour Doppler showing artery (red dotted line) 
and dilated vein (blue) of a Yellow markers indicate the region from which pulsed wave 
Doppler was acquired. (B,D) Pulsed wave Doppler measurement of blood flow demonstrates 
a high arterial flow velocity wave form within the artery (B), and a slow venous flow velocity 
wave form within the dilated vein (D). (E) Power Doppler ultrasound demonstrates slow flow 
signals in subcutaneous vascular malformation. 
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Figure S5 
 
 
Figure S5. Representative images of immunostaining for lymphatic markers (LYVE-1, 
PROX-1) in VMs of MosMes-Pik3caH1047R mice. Left, LYVE-1 immunostaining, original 
magnification x100 (x40, inner square). Right, PROX-1 immunostaining, original 
magnification x100. 
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Figure S6 
 
Figure S6. Genetic strategy to activate Pik3caH1047R in ECs. Pdgfb-iCreER mice were crossed 
with Pik3caWT/H1047R mice.  
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Figure S7 
 
Figure S7. Expression of VE-Cadherin in P6 EC-Pik3caH1047R retinas. VE-Cadherin mRNA 
expression was normalized to Hprt. Data represent mean  SEM. (Mann-Whitney U test) *p 
< 0.05. n=5/genotype. 
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Figure S8 
 
Figure S8. Apoptosis in P9 EC-Pik3caH1047R retinas. (A) Representative flat-mounted 
Pik3caWT and EC-Pik3caH1047R P9 retinas, stained with IB4 (green, revealing ECs) and with 
antibody to cleaved caspase-3 (marker of apoptosis; red). Indicated are apoptotic ECs (orange 
arrows) and non-EC apoptotic cells (white arrowheads). (B) Higher magnification of sections 
highlighted in (A). 
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Figure S9 
 
Figure S9. (A) Expression of Pdgfb in EC-Pik3caH1047R lungs. Data represent mean  SEM. 
(Mann-Whitney U test). (B) Expression of Ephb4, Nr2f2 and Efnb2 mRNA in lung lysates of 
Pik3caWT and EC-Pik3caH1047R P6 mice. Data represent mean  SEM. *p < 0.05 (Mann-
Whitney U test). n=5/genotype. 
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Figure S10 
 
Figure S10. Treatment of MosMes-Pik3caH1047R mice with rapamycin. (A) 3D image 
reconstruction of CT-A of  MosMes-Pik3caH1047R mouse #3 before treatment, subcutaneous 
VM highlighted in red. (B) CT-A images MosMes-Pik3caH1047R mouse #3 upon rapamycin 
treatment showing the volume of the subcutaneous VM (circled in blue). (C) Graph showing 
volumes of VM from MosMes-Pik3caH1047R mice during rapamycin treatment. (D) Graph 
showing average diameter of inferior vena cava and portal vein of MosMes-Pik3caH1047R 
mice during rapamycin treatment. 
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Supplementary Table 1. List of organs and tissues subjected to histological examination 
(H&E staining) in WT and MosMes-Pik3caH1047R mice 
 
Adrenals Ovaries/oviducts 
Aorta Pancreas 
Brain Parathyroids 
Caecum Prostate 
Cervix Rectum 
Colon Salivary gland 
Duodenum Seminal vesicles 
Epididymis Skeletal muscle 
Eyes Skin 
Perigenital fat pad Spleen 
Perirenal fat pad Sternum 
Femur Stomach 
Heart Submandibular lymph nodes 
Ileum Testes 
Jejunum Thymus 
Kidneys Thyroids 
Liver Tongue 
Lungs Trachea 
Mammary glands Urinary bladder 
Oesophagus Uterus/vagina 
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Supplementary Table 2. Percentage of MosMes-Pik3caH1047R mice with VMs after dosing 
pregnant females with different doses of 4-OHT 
 
µg 4-OHT 
administered per 
pregnant mouse 
MosMes-Pik3caH1047R mice 
with VMs 
12.5 12.5% 
50 15% 
250 100% 
  
 
Supplementary Table 3. Percentage of live WT and MosMes-Pik3caH1047R offspring 
obtained after administration of different doses of 4-OHT to pregnant females. The expected 
normal Mendelian distribution is 50% of each genotype. 
 
 observed frequency 
µg 4-OHT 
administered per pregnant 
mouse  
WT MosMes-Pik3caH1047R 
12.5 50.0% 50.0% 
50 48.7% 51.3% 
250 61.5% 38.5% 
 
 
